Significant increase in earnings and margins – positive outlook for 2025

Press release

Preliminary figures for Medios AG 2024: Significant increase in earnings and margins – positive outlook for 2025

Preliminary figures 2024

• Revenue increases to around €1.9 billion (+5.5%)
• Disproportionate increase of EBITDA pre¹ to around €79 million (+31%); EBITDA pre¹ margin significantly improved to around 4.2% (previous year: 3.4%)
• Sharp increase in cash flow from operating activities

 Outlook for 2025

• Revenue increase to around €2 billion (+6%)
• EBITDA pre¹ increase of around 21.5% to around €96 million

Berlin, March 4, 2025 – Medios AG ("Medios"), a leading provider of Specialty Pharma in Europe, has once again achieved record revenues and earnings in the 2024 financial year based on preliminary and unaudited figures (IFRS). Consolidated revenue increased year-on-year to approximately €1.9 billion (previous year: €1.8 billion). EBITDA pre¹ increased significantly by around 31% to approx. €79 million (previous year: €60.5 million). The EBITDA pre¹ margin also improved significantly to 4.2% (previous year: 3.4%). The disproportionate increase in EBITDA pre¹ is due in particular to the acquisition of the Ceban Group and the associated internationalization. Cash flow from operating activities also reached a new record of around €74 million due to an increase in the operating result and a reduction in net working capital as of the reporting date. The financial results for 2024 are therefore largely in line with the adjusted guidance issued on December 12, 2024.

Matthias Gaertner, CEO of Medios AG: “Despite the ongoing geopolitical and economic challenges, we continued to make great strides in implementing our growth strategy and generated new record figures for revenue and earnings. We also further strengthened our core business in Germany and showed that we can generate a high cash flow with our business model. With the tailwind of this strong performance, we are looking ahead to the current financial year with great confidence and aim to reach the 2-billion-euro revenue mark while further improving profitability.”

Positive outlook for the 2025 financial year

For the 2025 financial year, the Medios Group expects an increase in sales revenues to approximately €2 billion. The EBITDA pre¹ is expected to increase disproportionately again to around €96 million. This corresponds to a further increase in the EBITDA pre¹ margin to around 4.8%. This expectation is based on the assumption of organic growth in the mid-single-digit percentage range and takes the consolidation of the Ceban Group for twelve months into account.

The complete 2024 Annual Report will be published on March 25, 2025, and will be available for download on the Investor Relations website.

Important dates for Medios AG in the 2025 financial year:

-------------------

About Medios AG

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany's first listed specialty pharmaceutical company. The shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

www.medios.ag

Contact

Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.group

Disclaimer

This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.